Prevention of Diabetes Using Mobile-enabled, Virtual Delivery of the National Diabetes Prevention Program
Launched by NOOM INC. · Mar 5, 2019
Trial Information
Current as of April 30, 2025
Completed
Keywords
ClinConnect Summary
There were 84.1 million people with pre-diabetes, 30.3 million people with diagnosed and 7.2 million with undiagnosed diabetes in the United States in 2015, and nearly 2 million are diagnosed with it every year. By 2050, the CDC estimates that 1 in every 3 people globally will have diabetes, a leading cause of death and disability.
The primary goal of this study is to evaluate the efficacy of the Noom Coach Diabetes Prevention Program mobile platform versus usual medical care. The best intervention to date for prediabetes is the Centers for Disease Control and Prevention's Diabetes Prevent...
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • English-speaking
- • 18 years of age and older
- • Referral from the patient's physician
- • Hemoglobin A1C: 5.7 - 6.4 within the 3 months prior to enrollment
- • Own a smartphone (Apple or Android)
- Exclusion criteria:
- • Recent weight loss (by patient report, \>5 lbs in the 6 months preceding enrollment visit)
- • previous diagnosis of type 1 or type 2 diabetes
- • serious or persistent mental illnesses
- • more than 72 hours of hospitalization in the last 30 days
- • Enrollment in a structured weight-loss program currently or within the 1 month preceding study enrollment
- • Pregnant
- • Currently nursing
- • Have given birth within the past 3 months
- • Has been discouraged by a physician to enroll in a DPP program
About Noom Inc.
Noom Inc. is a leading digital health company dedicated to empowering individuals to achieve sustainable weight loss and improve overall wellness through innovative technology and personalized coaching. Leveraging a blend of psychology, behavior change principles, and data-driven insights, Noom's platform offers tailored programs that promote healthy habits and lifestyle modifications. With a commitment to scientific rigor, Noom actively engages in clinical trials to evaluate the efficacy of its interventions, aiming to contribute to the broader understanding of weight management and chronic disease prevention. Through its user-centric approach, Noom Inc. strives to transform health outcomes and enhance the quality of life for its users.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stony Brook, New York, United States
Patients applied
Trial Officials
Joshua D Miller, MD, MPH
Principal Investigator
Stony Brook University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials